Zonisamide Market available in the latest report forecast by 2029

1.9.2023: New Market Research Report Reveals Key Insights into the Zonisamide Market, Valued at USD 353.26 Million in 2022

Report Scope and Methodology:

Report Scope: The comprehensive research report explores the Zonisamide Market, its drivers, restraints, and regional insights. It offers a detailed analysis of market dynamics, trends, and growth opportunities in the industry. The report covers segments such as strength (25 mg, 50 mg, and 100 mg) and application (adult, pediatric, and geriatric).

Research Methodology: The report is based on extensive research, incorporating data from 2022 as a base year, real numbers, outputs from key players, and global market leaders. It considers the impact of the COVID-19 pandemic and analyzes trends over the past five years while projecting market trends through 2029.

For detail insights on this market, request for methodology here @

https://www.maximizemarketresearch.com/market-report/zonisamide-market/148295/

What are Zonisamide Market Dynamics?

Drivers:

Rising Epilepsy Cases: Epilepsy affects around 50 million people worldwide, making it one of the most common neurological disorders. With approximately 2.4 million new cases diagnosed each year, the increase in epilepsy cases drives the demand for Zonisamide.

Second-Generation Antiepileptic Drugs: Second-generation antiepileptic drugs, including Zonisamide, offer benefits such as reduced drug interactions and side effects, driving their adoption.

Growing Geriatric Population: The elderly population is increasingly affected by epilepsy due to factors such as stroke and brain tumors. With a rising geriatric population, the demand for Zonisamide is expected to increase.

Restraints:

Drug Supply Shortages: A sharp increase in drug supply shortages poses a significant challenge to the Zonisamide market. Patients stockpile medicines due to shortages, leading to concerns about the global medicine supply chain.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @

https://www.maximizemarketresearch.com/request-sample/148295

Zonisamide Market Segmentation?

Based on Strength:

25 mg: This strength variant caters to patients requiring lower doses of Zonisamide. It may be prescribed according to individual patient needs.

50 mg: The 50 mg tablet dominates the market segment, making it a preferred choice for both patients and physicians. It is often prescribed twice a day or as a single 100 mg dose.

100 mg: Zonisamide is also available in 100 mg tablets, suitable for patients requiring higher doses. Physicians may prescribe it according to the specific needs of patients.

Based on Application:

Adult: Zonisamide is widely used in the adult population, serving as an effective treatment for epilepsy. It addresses the needs of adult patients affected by the condition.

Pediatric: While the pediatric segment shows moderate growth, Zonisamide is also prescribed for children aged between 0 to 17 years who have active epilepsy. The common dosage in pediatrics is typically 2 mg/kg, tailored to individual patient requirements.

Who are Zonisamide Market Key Players?
1. Concordia
2. Eisai
3. Zydus Pharmaceuticals
4. Sun Pharma
5. Wockhardt
6. Mylan
7. APOTEX
8. Teva
9. Glenmark
10. Bluepharma
11. Invagen Pharmaceuticals
12. Intas Pharmaceuticals

Please connect with our representative, who will ensure you to get a report sample here @

https://www.maximizemarketresearch.com/request-sample/148295

Regional Insights:

North America: The dominant market for Zonisamide, North America, accounted for 30% of the market share in 2022. With approximately 3 million epilepsy patients in the region, it boasts a well-developed healthcare infrastructure and government initiatives to improve healthcare.

Asia Pacific: Expected to grow during the forecast period, the Asia Pacific region benefits from increased government funding, improved treatment facilities, and rising disposable income. India, as a pharmaceutical hub, plays a pivotal role in this region's growth.

South America, the Middle East, and Africa: These regions are in the early stages of Zonisamide market development, driven by improved medical infrastructure and increased epilepsy prevalence.

Related Reports:

Global Torsional Vibration Dampers Market https://www.maximizemarketresearch.com/market-report/global-torsional-vibration-dampers-market/111718/

Global Hybrid Power Solutions Market https://www.maximizemarketresearch.com/market-report/global-hybrid-power-solutions-market/115583/

Synthetic Natural Gas (SNG) Market https://www.maximizemarketresearch.com/market-report/synthetic-natural-gas-sng-market/66999/

Global Industrial V-belt Market https://www.maximizemarketresearch.com/market-report/global-industrial-v-belt-market/91830/

Global Uncoated Paint Protection Film Market https://www.maximizemarketresearch.com/market-report/global-uncoated-paint-protection-film-market/25859/

Global Monolithic Microwave IC (MMIC) Market https://www.maximizemarketresearch.com/market-report/global-monolithic-microwave-ic-mmic-market/29699/

Contact Maximize Market Research:

MAXIMIZE MARKET RESEARCH PVT. LTD.
⮝ 444 West Lake Street, Floor 17,
Chicago, IL, 60606, USA.
✆ +1 800 507 4489
✆ +91 9607365656
🖂 sales@maximizemarketresearch.com
🌐 www.maximizemarketresearch.com

About Maximize Market Research:

Maximize Market Research is a swiftly growing enterprise that specializes in market research and corporate advisory services, serving clients globally. With our substantial impact on revenue and unwavering commitment to research excellence, we have positioned ourselves as a trusted partner to a significant portion of Fortune 500 companies. Our comprehensive range of services caters to a diverse array of industries, including but not limited to IT, telecommunications, chemicals, food and beverages, aerospace and defense, healthcare, and beyond.

This release was published on openPR.